The industry-funded ARM Foundation for Cell and Gene Medicine has launched a new health economic analysis of regenerative medicine therapies, which includes a review of academic literature, health technology assessments, and value frameworks.
The so-called ‘ landscape assessment,’ which was performed by industry analyst IQVIA on behalf of the Foundation, is intended as a first step towards a new cost-effectiveness methodology for regenerative medicines.
Such a framework could be used to rival assessments provided by the Institute for Clinical and Economic Review (ICER), a group that is perceived as providing more payer-friendly analyses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze